Sebastian Bernales

Sebastian Bernales is a General Partner at Humboldt Fund and a Venture Partner at DROIA Ventures, currently based in San Francisco, California. Before co-founding Humboldt Fund in 2020, he served as Vice President of Discovery Biology at Medivation, where he contributed to the development of the prostate cancer drug Xtandi prior to the company's $14 billion acquisition by Pfizer in 2016. As an active biotechnology entrepreneur, he co-founded the gene-editing therapy developer Metagenomi and previously served as the Chief Executive Officer of Praxis Biotech. Bernales earned a doctorate in cell biology from the University of California, San Francisco, and holds a biochemistry degree from the Pontificia Universidad Católica de Chile. Today, his venture capital investment focus centers on funding early-stage biotechnology startups that are developing innovative therapeutics across gene editing, cell-based therapies, and mitochondrial diseases.